Mavacamten
- Generic Name
- Mavacamten
- Brand Names
- Camzyos
- Drug Type
- Small Molecule
- Chemical Formula
- C15H19N3O2
- CAS Number
- 1642288-47-8
- Unique Ingredient Identifier
- QX45B99R3J
- Background
Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. Mavacamten was also approved by Health Canada in October 2022 and ...
- Indication
Mavacamten is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms by the FDA, Health Canada, and the EMA.
- Associated Conditions
- Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Associated Therapies
- -
A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 420
- Registration Number
- NCT05582395
- Locations
- 🇦🇺
Local Institution - 0078, Milton, Queensland, Australia
🇦🇺Local Institution - 0050, Bedford Park, South Australia, Australia
🇦🇺Local Institution - 0076, Murdoch, Western Australia, Australia
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
- Conditions
- Interventions
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1600
- Registration Number
- NCT05489705
- Locations
- 🇦🇹
Local Institution - 0087, Graz, Austria
🇦🇹Local Institution - 0082, Braunau am Inn, Austria
🇦🇹Local Institution - 0088, Innsbruck, Austria
A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy
- Conditions
- Interventions
- First Posted Date
- 2022-06-10
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 38
- Registration Number
- NCT05414175
- Locations
- 🇯🇵
Local Institution - 0026, Himeji-Shi, Hyogo, Japan
🇯🇵Local Institution - 0020, Uwajima, Ehime, Japan
🇯🇵Local Institution - 0016, Kobe-shi, Hyogo, Japan
A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2022-11-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 158
- Registration Number
- NCT05362045
- Locations
- 🇺🇸
Clinical pharmacology of Miami, Miami, Florida, United States
🇺🇸Advanced Pharma CR, LLC, Miami, Florida, United States
🇺🇸Ppd Phase I Clinic, Austin, Texas, United States
A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 45
- Registration Number
- NCT05320094
- Locations
- 🇺🇸
Local Institution - 0001, Dallas, Texas, United States
A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
- Conditions
- Interventions
- First Posted Date
- 2021-12-30
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- LianBio LLC
- Target Recruit Count
- 81
- Registration Number
- NCT05174416
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- LianBio LLC
- Target Recruit Count
- 45
- Registration Number
- NCT05135871
- Locations
- 🇨🇳
Huashan Hospital Fudan University, Shanghai, Shanghai, China
A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT
- Conditions
- Interventions
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT04766892
- Locations
- 🇺🇸
Local Institution - 0014, Miami, Florida, United States
🇺🇸Local Institution - 0011, Tucson, Arizona, United States
🇺🇸Local Institution - 0005, Los Angeles, California, United States
A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy
- Conditions
- Interventions
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 112
- Registration Number
- NCT04349072
- Locations
- 🇺🇸
Local Institution, Houston, Texas, United States
🇺🇸Local Institution - 0015, Rochester, Minnesota, United States
🇺🇸Local Institution - 0002, Portland, Oregon, United States
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
- Conditions
- Interventions
- First Posted Date
- 2018-10-29
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 282
- Registration Number
- NCT03723655
- Locations
- 🇮🇱
Local Institution - 0023, Safed, Israel
🇵🇹Local Institution - 0036, Almada, Portugal
🇮🇱Local Institution - 0022, Ramat-gan, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.